Incyte Corporation (INCY) Stock Score, Valuation & Financial Research
Incyte Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 65/100.
Quick answer for INCY
Incyte Corporation currently has a Wall Street Score of 65/100. The stored market price is $121.47. Its financial score is 45/100. Its valuation score is 93/100. The latest WSS change is +1.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What Incyte Corporation does
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma,
INCY financial snapshot
- Wall Street Score:
- 65/100
- Current price:
- $121.47
- Market capitalization:
- $24.62B
- Revenue:
- $5.82B
- Net income:
- $1.61B
- Free cash flow:
- $1.35B
- Cash:
- $3.98B
- Total debt:
- $38.3M
- EPS:
- 6.59
- P/E ratio:
- 18.4x
- Financial score:
- 45/100
- Valuation score:
- 93/100
- Revenue score:
- 48/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $1.35B, showing positive cash generation.
- The balance sheet shows $3.98B of cash versus $38.3M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +1.2 points: INCY increased 1.2 points because Revenue improved by 9.8 points, Capital improved by 3 points, Buffett improved by 2 points.
What the numbers mean
Its current valuation score is 93/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 45/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research INCY
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.